Genmab A/S (NASDAQ:GMAB) Upgraded at BNP Paribas

BNP Paribas upgraded shares of Genmab A/S (NASDAQ:GMAB) from a strong sell rating to a hold rating in a research report released on Tuesday morning,Zacks.com reports.

Several other equities analysts have also recently issued reports on GMAB. BMO Capital Markets restated an “outperform” rating and set a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Finally, Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a report on Thursday. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $42.17.

Genmab A/S Stock Up 6.2 %

NASDAQ:GMAB opened at $20.92 on Tuesday. The firm’s fifty day simple moving average is $20.68 and its 200 day simple moving average is $23.21. The stock has a market cap of $13.84 billion, a P/E ratio of 20.31, a price-to-earnings-growth ratio of 0.54 and a beta of 0.96. Genmab A/S has a twelve month low of $18.64 and a twelve month high of $31.88.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. On average, analysts expect that Genmab A/S will post 1.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its stake in Genmab A/S by 7.8% during the fourth quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company’s stock worth $40,199,000 after buying an additional 139,722 shares during the period. Brandywine Global Investment Management LLC purchased a new stake in shares of Genmab A/S in the 4th quarter valued at approximately $33,804,000. Marshall Wace LLP lifted its position in shares of Genmab A/S by 162.2% during the 4th quarter. Marshall Wace LLP now owns 1,122,296 shares of the company’s stock worth $23,422,000 after purchasing an additional 694,243 shares during the last quarter. Two Sigma Advisers LP increased its holdings in Genmab A/S by 84.1% in the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock valued at $14,996,000 after buying an additional 280,900 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of Genmab A/S by 18,959.1% in the 4th quarter. Russell Investments Group Ltd. now owns 510,784 shares of the company’s stock valued at $10,660,000 after acquiring an additional 508,104 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.